All‐cause mortality · patients with heart failure
Coenzyme Q10 probably leads to lower all‐cause mortality compared with placebo or conventional therapy (moderate certainty).
1 finding from 1 review
Myocardial infarction · patients with heart failure
Coenzyme Q10 showed no clear difference in myocardial infarction compared with placebo or conventional therapy (low certainty).
1 finding from 1 review
Stroke · patients with heart failure
Coenzyme Q10 showed no clear difference in stroke compared with placebo or conventional therapy (low certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · patients with heart failure
Coenzyme Q10 probably leads to lower hospitalisation for heart failure compared with placebo or conventional therapy (moderate certainty).
1 finding from 1 review
Left ventricular ejection fraction (%) · patients with heart failure
1 finding from 1 review
Exercise capacity · patients with heart failure
1 finding from 1 review
Adverse events · patients with heart failure
Coenzyme Q10 showed no clear difference in adverse events compared with placebo or conventional therapy (low certainty).
1 finding from 1 review
Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Economic outcomes · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Intervention not reported
End of treatment SBP (over 12 weeks) · patients with primary hypertension
1 finding from 1 review
Intervention not reported
End of treatment DBP (over 12 weeks) · patients with primary hypertension
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse effects · patients with primary hypertension
1 finding from 1 review